Keywords: sanofi, lovenox, shows, benefit, stemi, french, drug
Sanofi's Lovenox shows benefit in STEMI
Article | 10 September 2007
French drug major Sanofi-Aventis says that one-year data from the ExTRACT-TIMI 25 and STEEPLE studies confirm that its anti-thrombotic Lovenox (enoxaparin) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
